Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues

被引:38
作者
Appiah-Opong, Regina [1 ]
de Esch, Iwan
Commandeur, Jan N. M. [1 ]
Andarini, Mayagustina [1 ]
Vermeulen, Nico P. E. [1 ]
机构
[1] Vrije Univ Amsterdam, Dept Pharmacochem, Leiden Amsterdam Ctr Drug Res LACDR, Div Mol Toxicol, NL-1081 HV Amsterdam, Netherlands
关键词
cytochrome P450; curcumin analogues; inhibition; drug-drug interactions; (Q)SAR;
D O I
10.1016/j.ejmech.2007.10.034
中图分类号
R914 [药物化学];
学科分类号
100701 [药物化学];
摘要
Inhibition of cytochrome P450 (CYP) is a major cause of drug-drug interactions. In this work, inhibitory potentials of 33 curcumin analogues, i.e. 2,6-dibenzylidenecyclohexanone (A series), 2,5-dibenzylidenecyclopentanone (B series) and 1,4-pentadiene-3-one (C series) substituted analogues of curcumin towards recombinant human CYP1A2, CYP3A4, CYP2B6, CYP2C9 and CYP2D6, all important for drug metabolism, were studied in vitro. Fluorescence plate reader and high performance liquid chromatography (HPLC) assays were used to evaluate CYP-inhibitory activities. MOE-based Quantitative structure-activity relationship (QSAR) analysis suggested that electrostatic and hydrophobic interactions and lipophilicity are important factors for CYP inhibition. Apart from insights in important molecular properties for CYP inhibition, the present results may also guide further design of curcumin analogues with less susceptibility to drug-drug interactions. (c) 2007 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:1621 / 1631
页数:11
相关论文
共 33 条
[1]
Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents [J].
Adams, BK ;
Ferstl, EM ;
Davis, MC ;
Herold, M ;
Kurtkaya, S ;
Camalier, RF ;
Hollingshead, MG ;
Kaur, G ;
Sausville, EA ;
Rickles, FR ;
Snyder, JP ;
Liotta, DC ;
Shoji, M .
BIOORGANIC & MEDICINAL CHEMISTRY, 2004, 12 (14) :3871-3883
[2]
ROLE OF SUBSTRATE LIPOPHILICITY IN DETERMINING TYPE-1 MICROSOMAL P450 BINDING CHARACTERISTICS [J].
ALGAILANY, KAS ;
HOUSTON, JB ;
BRIDGES, JW .
BIOCHEMICAL PHARMACOLOGY, 1978, 27 (05) :783-788
[3]
Antimutagenic and anticarcinogenic activity of natural and synthetic curcuminoids [J].
Anto, RJ ;
George, J ;
Babu, KV ;
Rajasekharan, KN ;
Kuttan, R .
MUTATION RESEARCH-GENETIC TOXICOLOGY, 1996, 370 (02) :127-131
[4]
APPIAHOPONG R, 2007, TOXICOLOGY MAR
[5]
The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties [J].
Austin, RP ;
Barton, P ;
Cockroft, SL ;
Wenlock, MC ;
Riley, RJ .
DRUG METABOLISM AND DISPOSITION, 2002, 30 (12) :1497-1503
[6]
ETHOXYPHENOXAZONES, PENTOXYPHENOXAZONES, AND BENZYLOXYPHENOXAZONES AND HOMOLOGS - A SERIES OF SUBSTRATES TO DISTINGUISH BETWEEN DIFFERENT INDUCED CYTOCHROMES-P-450 [J].
BURKE, MD ;
THOMPSON, S ;
ELCOMBE, CR ;
HALPERT, J ;
HAAPARANTA, T ;
MAYER, RT .
BIOCHEMICAL PHARMACOLOGY, 1985, 34 (18) :3337-3345
[7]
Cheng AL, 2001, ANTICANCER RES, V21, P2895
[8]
NSAID and antioxidant prevention of Alzheimer's disease lessons from in vitro and animal models [J].
Cole, GM ;
Morihara, T ;
Lim, GP ;
Yang, FS ;
Begum, A ;
Frautschy, SA .
PROTECTIVE STRATEGIES FOR NEURODEGENERATIVE DISEASES, 2004, 1035 :68-84
[9]
Cytochrome P450-mediated oxidation of glucuronide derivatives:: Example of estradiol-17β-glucuronide oxidation to 2-hydroxyestradiol-17β-glucuronide by CYP2C8 [J].
Delaforge, M ;
Pruvost, A ;
Perrin, L ;
André, F .
DRUG METABOLISM AND DISPOSITION, 2005, 33 (03) :466-473
[10]
Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: Potent inhibition of CYP2C19 and CYP3A [J].
Desta, Z ;
Soukhova, NV ;
Flockhart, DA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (02) :382-392